4142:TPE
Adimmune Corp
15,85 NT$
arrow_downward
-1,86%(-0,30) 1D
19 nën, 1:30:08 m.d., GMT+8 · TWD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 4142...
Hap
16,20 NT$
I lartë
16,25 NT$
I ulët
15,70 NT$
Kapitalizimi i tregut
6,81 mld
Vëllimi mesatar
1,09 mln
Vëllimi
1,60 mln
Raporti çmim/fitim
91,85
Maksimumi 52-javor
21,50 NT$
Minimumi 52-javor
15,65 NT$
Fitimet për aksion
0,17 NT$
Aksionet në qarkullim
235,29 mln
Numri i punonjësve
564
Hap
16,20 NT$
I lartë
16,25 NT$
I ulët
15,70 NT$
Kapitalizimi i tregut
6,81 mld
Vëllimi mesatar
1,09 mln
Vëllimi
1,60 mln
Raporti çmim/fitim
91,85
Maksimumi 52-javor
21,50 NT$
Minimumi 52-javor
15,65 NT$
Fitimet për aksion
0,17 NT$
Aksionet në qarkullim
235,29 mln
Numri i punonjësve
564
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
The Harvard Law School Forum on Corporate Governance
·
6 orë më parë
Board Practices and Composition in the Russell 3000 and S&P 500
Benzinga
·
1 orë më parë
Anthropic Jumps 27% in Record Debut, S&P 500 Eyes Sixth Straight Loss: Stock Market Today
The Motley Fool
·
8 orë më parë
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
24/7 Wall St.
·
1 orë më parë
S&P 500 Drops Nearly 1% at Midday While the Dow Slides 1.5%
Profili
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Rreth Adimmune Corp
Drejtori ekzekutiv-
Punonjësit564
Themeluar më1965
Selia-
SektoriHealth Care
Industria-
Uebsajtiadimmune.com.tw